SCHEMBL6925643

SCHEMBL6925643

COc1ccc(N)cc1OCCN(C)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HTT P42858 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
USP2 O75604 2/20 0.40
CYP19A1 P11511 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
HTR2A P28223 2/20 0.39
HTR2C P28335 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204180 0.87 GAA (0.47) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL1220219 0.84 HTR7 (0.53) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL6921862 0.83 GAA (0.48) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL6200318 0.82 GAA (0.46) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL6927309 0.82 GAA (0.43) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL4198415 0.81 GAA (0.55) GAAALDH1A1MAPTKDM4EHTR2C
SCHEMBL188792 0.80 GAA (0.50) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL3616464 0.79 BIRC5 (0.54) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL5275674 0.78 GAA (0.60) GAAALDH1A1MAPTKDM4EHTT
SCHEMBL29875923 0.78 GAA (0.60) GAAALDH1A1MAPTKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP disclosed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 US disclosed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 EP disclosed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP disclosed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO disclosed